[go: up one dir, main page]

WO2016029113A1 - Procédés d'augmentation de la production endogène de bêta-hydroxy-bêta-méthylbutyrate - Google Patents

Procédés d'augmentation de la production endogène de bêta-hydroxy-bêta-méthylbutyrate Download PDF

Info

Publication number
WO2016029113A1
WO2016029113A1 PCT/US2015/046292 US2015046292W WO2016029113A1 WO 2016029113 A1 WO2016029113 A1 WO 2016029113A1 US 2015046292 W US2015046292 W US 2015046292W WO 2016029113 A1 WO2016029113 A1 WO 2016029113A1
Authority
WO
WIPO (PCT)
Prior art keywords
nutritional composition
prebiotic
subject
protein
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2015/046292
Other languages
English (en)
Inventor
María del Pilar BUENO VARGAS
José María LÓPEZ PEDROSA
Manuel Cristóbal MANZANO MARTÍN
Ángela SANTOS-FANDILA
Enrique VÁQUEZ HERNANDEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of WO2016029113A1 publication Critical patent/WO2016029113A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L9/00—Puddings; Cream substitutes; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates

Definitions

  • the general inventive concepts relate to nutritional compositions and methods of increasing endogenous production of beta-hydroxy-beta-methylbutyrate (HMB) in a subject. More particularly, the general inventive concepts relate to the administration of a nutritional composition comprising a prebiotic to a subject to increase endogenous production of HMB in the subject.
  • HMB beta-hydroxy-beta-methylbutyrate
  • Beta-hydroxy-beta-methylbutyrate is a metabolite of the branched-chain amino acid leucine. In general, approximately 5% to 10% of the leucine ingested by a human is metabolized to HMB. Accordingly, humans endogenously synthesize about 0.2 to 0.5 grams of HMB per day, depending on the amount of dietary leucine consumed. Studies have indicated that dietary supplementation with HMB may attenuate muscle protein degradation, increase lean body mass, and increase strength. Prebiotics are typically non-digestible compounds that pass undigested through the upper part of the gastrointestinal tract. These compounds are beneficial to host organisms because they can selectively stimulate the growth and/or activity of bacteria in the colon and thereby improve the health of the gastrointestinal tract.
  • HMOs Human milk oligosaccharides
  • the general inventive concepts relate to nutritional compositions and methods of increasing endogenous production of HMB in a subject. To illustrate various aspects of the general inventive concepts, several exemplary embodiments of nutritional compositions and methods are provided herein.
  • the invention provides a method of increasing endogenous production of beta-hydroxy-beta-methylbutyrate (HMB) in a subject.
  • the method comprises administering a nutritional composition to the subject, wherein the composition comprises a prebiotic. Consumption of the nutritional composition comprising the prebiotic increases endogenous levels of beta-hydroxy-beta methylbutyrate in the subject.
  • a composition comprising a prebiotic for use in a method of increasing endogenous production of beta-hydroxy-beta-methylbutyrate in a subject, the method comprising administering the composition to the subject.
  • use of a nutritional composition comprising a prebiotic for the manufacture of a medicament for increasing endogenous production of beta-hydroxy-beta-methylbutyrate in a subject.
  • the invention provides a method of increasing endogenous production of beta-hydroxy-beta-methylbutyrate in an offspring of a subject.
  • the method comprises administering a nutritional composition comprising a prebiotic to the subject during gestation. Consumption of the nutritional composition comprising the prebiotic by the subject increases endogenous levels of beta-hydroxy-beta methylbutyrate in the offspring in the womb.
  • a composition comprising a prebiotic for use in a method of increasing endogenous production of beta-hydroxy-beta-methylbutyrate in an offspring of a subject, the method comprising administering the composition to the subject during gestation.
  • use of a nutritional composition comprising a prebiotic for the manufacture of a medicament for increasing endogenous production of beta-hydroxy- beta-methylbutyrate in an offspring of a subject.
  • the invention provides a method of increasing endogenous production of beta-hydroxy-beta-methylbutyrate in an offspring of a subject.
  • the method comprises administering a nutritional composition comprising a prebiotic to the subject following delivery of the offspring and during breastfeeding of the offspring by the subject. Consumption of the nutritional composition comprising the prebiotic by the subject increases endogenous levels of beta-hydroxy-beta methylbutyrate in the offspring.
  • a composition comprising a prebiotic for use in a method of increasing endogenous production of beta-hydroxy-beta-methylbutyrate in an offspring of a subject, the method comprising administering the composition to the subject following delivery of the offspring and during breastfeeding of the offspring.
  • use of a nutritional composition comprising a prebiotic for the manufacture of a medicament for increasing endogenous production of beta-hydroxy-beta-methylbutyrate in an offspring of a subject.
  • the invention provides a method of promoting muscle hypertrophy and/or preventing muscle atrophy in a subject.
  • the method comprises administering a nutritional composition comprising a prebiotic to the subject.
  • a composition comprising a prebiotic for use in promoting muscle hypertrophy and/or preventing muscle atrophy in a subject, the method comprising administering the composition to the subject.
  • use of a nutritional composition comprising a prebiotic for the manufacture of a medicament for promoting muscle hypertrophy and/or preventing muscle atrophy in a subject.
  • the invention provides a method of improving brain development and/or cognitive function in a subject.
  • the method comprises administering a nutritional composition comprising a prebiotic to the subject.
  • a composition comprising a prebiotic for use in improving brain development and/or cognitive function in a subject the method comprising administering the composition to the subject.
  • use of a nutritional composition comprising a prebiotic for the manufacture of a medicament for improving brain development and/or cognitive function in a subject provides a method of treating a disease or condition selected from: sarcopenia, muscle wasting diseases, hyperglycaemia, glucose intolerance and neurodegenerative diseases.
  • the method comprises administering a nutritional composition comprising a prebiotic to the subject.
  • a composition comprising a prebiotic for use in the prevention or treatment of a disease or condition selected from: sarcopenia, muscle wasting diseases, hyperglycaemia, glucose intolerance and neurodegenerative diseases, said method comprising administration of a nutritional composition comprising a prebiotic.
  • the prebiotic may be selected from the group consisting of short chain fructooligosaccharides, long chain
  • the prebiotic comprises fructooligosaccharides having an average degree of polymerization of 4 and high
  • the prebiotic is a human milk oligosaccharide, optionally a human milk oligosaccharide selected from the group consisting of 6'-sialyllactose (6'SL), lacto-N-neotetraose (LNnT), 3'- fucosyllactose (3'FL), 3'- sialyllactose (3'SL), and 2'-fucosyllactose (2'FL).
  • 6'-sialyllactose (6'SL), lacto-N-neotetraose (LNnT), 3'- fucosyllactose (3'FL), 3'- sialyllactose (3'SL), and 2'-fucosyllactose (2'FL).
  • Fig.1 HMB concentration in serum after gavage of 2'-FL A. Time course study of HMB in serum after gavage of 2'FL. B. Comparison of HMB levels in serum at time 0 (TO) and after 300 minutes (T300). Data are expressed as mean + SEM.
  • a nutritional composition in powder form may be reconstituted (upon addition of water or another liquid) to form a nutritional composition in liquid form.
  • the nutritional compositions disclosed herein include at least one of a source of protein, a source of carbohydrate, and a source of fat.
  • the nutritional compositions disclosed herein include a source of protein, a source of carbohydrate, and a source of fat.
  • the nutritional compositions disclosed herein are generally suitable for oral consumption by a human.
  • the nutritional liquid may also be formulated as a suspension, an emulsion, a solution, and so forth.
  • semi-solid refers to nutritional compositions that are intermediate in properties, such as rigidity, between solids and liquids.
  • Some exemplary semi-solids include puddings, yogurts, gels, gelatins, doughs, and so forth.
  • semi-liquid refers to nutritional compositions that are intermediate in properties, such as flow properties, between liquids and solids.
  • Some exemplary semi-liquids include thick shakes, liquid yogurts, liquid gels, and so forth.
  • administer should be understood to include providing a nutritional composition to a subject, the act of consuming a nutritional composition (self-administration), and combinations thereof.
  • administered should be understood to include providing a nutritional composition to a subject, the act of consuming a nutritional composition (self-administration), and combinations thereof.
  • methods disclosed herein may be practised with or without doctor supervision or other medical direction.
  • serving refers to an amount of the nutritional composition administered, or intended to be administered, to a subject in a single administration event.
  • the nutritional composition is packaged as a single serving.
  • the nutritional composition is packaged in a container containing multiple servings, wherein the container bears instructions on how to separate a single serving of the nutritional composition from the bulk nutritional composition.
  • prebiotic refers to a substantially non-digestible food ingredient that selectively stimulates the growth, the activity, or both of certain bacteria (e.g., bifidobacteria, lactobacilli) in the distal portion of the small intestine that includes the ileum, the cecum, and the colon.
  • bacteria e.g., bifidobacteria, lactobacilli
  • human milk oligosaccharide or “HMO” as used herein, unless otherwise specified, refers generally to a number of complex carbohydrates found in human breast milk that can be in acidic or neutral form, and to precursors thereof.
  • Exemplary non-limiting human milk oligosaccharides include 6'-sialyllactose (6'SL), lacto-N-neotetraose (LNnT), 3'- fucosyllactose (3'FL), and 3'-sialyllactose (3'SL), and 2'-fucosyllactose (2'FL).
  • subject refers to a mammal, including companion animals, livestock, laboratory animals, working animals, sport animals, and humans. In certain exemplary embodiments, the subject is a human.
  • Beta-hydroxy-beta-methylbutyrate is a metabolite of the branched-chain amino acid leucine.
  • mammals endogenously produce a small amount of HMB, which is typically in the range of about 0.2 grams to about 0.5 grams per day.
  • Some of the benefits that have been associated with the consumption of HMB include attenuation of muscle protein degradation, reduction in cardiovascular risk factors (e.g., total cholesterol, LDL cholesterol, systolic blood pressure), increased lean body mass, increased muscle cell integrity, increased strength, and reduced muscle soreness, just to name a few. Since the amount of HMB produced via leucine intake is relatively small, and the cost of HMB supplements is relatively high, alternative sources of HMB are desirable.
  • endogenous production is used herein to mean the production of HMB in the body following the ingestion of any suitable precursor molecule.
  • SCFAs Short-chain fatty acids
  • prebiotic fermentation by colonic microbiota produces HMB in addition to SCFAs, and that the HMB produced in the colon by prebiotic fermentation is absorbed by enterocytes and enters circulation where it is available for use by various organs and tissues (e.g., muscle, brain).
  • nutritional compositions and methods of increasing endogenous production of HMB in a subject are provided.
  • the increase in endogenous production of HMB may provide a variety of benefits including, but not limited to, attenuation of muscle protein degradation, reduction in cardiovascular risk factors (e.g., total cholesterol, LDL cholesterol, systolic blood pressure), increased lean body mass, increased muscle cell integrity, increased strength, and reduced muscle soreness.
  • cardiovascular risk factors e.g., total cholesterol, LDL cholesterol, systolic blood pressure
  • a nutritional composition comprising a prebiotic for use in increasing endogenous production of HMB in a subject and a method of increasing endogenous production of HMB in a subject.
  • the method includes administering a nutritional composition comprising a prebiotic to the subject. Consumption of the nutritional composition comprising the prebiotic increases endogenous levels of HMB in the subject.
  • the subject is a human.
  • the human may be an infant, an adolescent, an adult, or an elderly adult.
  • infant refers to a human having an age of up to 12 months.
  • adolescent refers to a human having an age of 12 months to 18 years.
  • adult refers to a human having an age of 18 years to 50 years.
  • yielderly adult refers to a human having an age of greater than 50 years.
  • the human may be a toddler or a child.
  • toddler refers to a human having an age of greater than one year up to three years of age.
  • child refers to a human having an age of greater than three years up to twelve years of age.
  • a nutritional composition comprising a prebiotic for use in increasing endogenous production of HMB in an offspring of a subject and a method of increasing endogenous production of HMB in an offspring of a subject.
  • the method includes administering a nutritional composition comprising a prebiotic to the subject during gestation. Consumption of the nutritional composition comprising the prebiotic during gestation increases endogenous levels of HMB in the offspring in the womb.
  • a nutritional composition comprising a prebiotic for use in increasing endogenous production of HMB in an offspring of a subject and a method of increasing endogenous production of HMB in an offspring of a subject is provided.
  • the method includes administering a nutritional composition comprising a prebiotic to the subject following delivery of the offspring and during breastfeeding of the offspring.
  • Consumption of the nutritional composition comprising the prebiotic by the subject during breastfeeding of the offspring increases endogenous levels of HMB in the offspring. While not wishing to be bound by any particular theory, it is believed that consumption of the nutritional composition comprising the prebiotic by the subject (e.g., a subject who breastfeeds her offspring) results in the endogenous production of HMB that subsequently enters circulation and the breast milk, and is transferred via the breast milk to the breastfeeding offspring to facilitate healthy development of the offspring.
  • the nutritional compositions comprise a prebiotic and may be formulated as and administered in any known or otherwise suitable oral product form.
  • oral administration and “administered orally” refer to any form of administration in which the nutritional composition is introduced into the subject's digestive system, including the stomach and small intestine.
  • oral administration includes nasogastric intubation, in which a tube is run through the nose to the stomach of the subject to administer food or drugs.
  • Any solid, liquid, semi-solid, semi-liquid, or powder product form, including combinations or variations thereof, are suitable for use in the exemplary embodiments described herein, provided that such forms allow for safe and effective oral delivery to the subject via oral consumption of the ingredients as also defined herein.
  • the exemplary nutritional compositions described herein may be formulated to include only the essential ingredients described herein, or may be modified with optional ingredients to produce a variety of different product forms.
  • the exemplary nutritional compositions include, in addition to a prebiotic, at least one of a source of protein, a source of carbohydrate, and a source of fat.
  • the nutritional compositions include a source of protein, a source of carbohydrate, and a source of fat.
  • the nutritional compositions also include vitamins, minerals, and combinations thereof.
  • the exemplary nutritional compositions described herein may be formulated with sufficient kinds and amounts of nutrients to provide a sole, a primary, or a supplemental source of nutrition.
  • the nutritional compositions may be specifically formulated for pregnant women, lactating women, infants, adolescents, adults, or elderly adults.
  • the nutritional composition is formulated as a solid nutritional composition.
  • suitable solid nutritional compositions for use herein include snack and meal replacement products, including those formulated as bars; sticks; cookies, breads, cakes, or other baked goods; frozen liquids; candy; breakfast cereals; reconstitutable powders, granulated solids, or other particulates; snack chips or bites; frozen or retorted entrees; and so forth.
  • the serving is within a range of about 25 grams to about 150 grams.
  • the nutritional composition is a solid nutritional composition, the subject is administered a single serving or multiple (e.g., two, three, four, or more) servings per day.
  • the nutritional composition is formulated as a nutritional liquid.
  • nutritional liquids include snack and meal replacement products, hot or cold beverages, carbonated or non-carbonated beverages, juices or other acidified beverages, milk or soy-based beverages, shakes, coffees, teas, and so forth.
  • These liquid compositions are most typically formulated as suspensions or emulsions, but can also be formulated in any other suitable form such as clear liquids, substantially clear liquids, solutions, and so forth.
  • a serving thereof may be about 30 milliliters to about 500 milliliters (-1 fl. oz. to -17 fl. oz.).
  • the serving when the nutritional composition is a liquid, the serving is about 237 milliliters ( ⁇ 8 fl. oz.). In other exemplary embodiments, when the nutritional composition is a liquid, the serving is about 177 milliliters to about 414 milliliters (-6 fl. oz. to -14 fl. oz.) or about 207 milliliters to about 296 milliliters ( ⁇ 7 fl. oz. to -10 fl. oz.). In other exemplary embodiments, when the nutritional composition is a liquid, the serving is about 30 milliliters to about 75 milliliters (-1 fl. oz. to -2.5 fl. oz.).
  • the subject when the nutritional composition is a liquid, the subject is administered a single serving or multiple (e.g., two, three, four, or more) servings per day.
  • the nutritional composition is formulated as one of a liquid, a liquid reconstituted from a powder, and a bar.
  • the nutritional composition is formulated as an emulsion.
  • the emulsion generally comprises a source of protein, a source of carbohydrate, and a source of fat.
  • the emulsions are flowable or drinkable liquids at from about 1 °C to about 25 °C and are typically in the form of oil-in-water, water-in-oil, or complex aqueous emulsions, although such emulsions are most typically in the form of oil-in-water emulsions having a continuous aqueous phase and a discontinuous oil phase.
  • the emulsion may have a pH ranging from about 3.0 to about 8.0, but is generally formulated with a pH in a range of from about 5.0 to about 8.0, including from about 6.0 to about 8.0, and also including from about 6.5 to about 7.5.
  • the nutritional composition may be formulated as a semisolid composition (e.g., puddings, yogurts, gels, gelatins, doughs) or a semi-liquid composition (e.g., thick shakes, liquid yogurts, liquid gels), as well as product forms such as capsules, tablets, caplets, pills, and so forth.
  • the nutritional composition may be formulated as lozenges, tablets (e.g., chewable, coated), pastes, gels, and so forth.
  • the nutritional compositions described herein may serve as a sole or supplemental source of nutrition. Accordingly, the nutritional compositions described herein may be formulated to provide a certain amount of energy per serving of the nutritional composition.
  • the nutritional composition provides up to 500 kcal of energy per serving, including from 20 kcal to 500 kcal, from 75 kcal to 500 kcal, from 150 kcal to 500 kcal, from 200 kcal to 500 kcal, from 300 kcal to 500 kcal, or from 400 kcal to 500 kcal per serving.
  • the exemplary nutritional compositions described herein include a prebiotic.
  • Exemplary prebiotics that may be utilized in the nutritional compositions and methods described herein include short chain fructooligosaccharides (FOS), long chain FOS, inulins, galactooligosaccharides (GOS), xylooligosaccharides (XOS), resistant starch, and combinations thereof.
  • Fructooligosaccharides (FOS) refer to oligosaccharides comprised of D-fructose and D-glucose.
  • Short chain FOS generally contain two to six monosaccharide units, whereas long chain FOS generally contain seven or more monosaccharide units.
  • FOS are resistant to digestion in the upper gastrointestinal tract, and stimulate the growth of Bifidobacterium species in the colon.
  • Inulins refer to a group of naturally-occurring fructose-containing oligosaccharides. Inulins belong to a class of carbohydrates known as fructans. They are derived from the roots of chicory (Cichorium intybus) and Jerusalem artichokes. Inulins are mainly comprised of fructose units and typically have a terminal glucose. The bond between fructose units in inulins is a beta-(2-1 ) glycosidic linkage. The average degree of polymerization of inulins marketed as nutritional supplements is 10 to 12. Inulins stimulate the growth of Bifidobacterium species in the colon.
  • Galactooligosaccharides are a mixture of oligosaccharides consisting of D-glucose and D-galactose.
  • the GOS may be produced from lactose via the action of the enzyme beta-galactosidase.
  • beta-galactosidase In general, GOS are resistant to digestion in the upper gastrointestinal tract and stimulate the growth of Bifidobacteria in the colon.
  • Xylooligosaccharides are comprised of oligosaccharides containing beta-linked xylose residues. The degree of polymerization of XOS is from two to four. XOS may be obtained by the enzymatic hydrolysis of the polysaccharide xylan.
  • Suitable prebiotics for use in the exemplary nutritional compositions and methods described herein include, but are not limited to, resistant starch, acacia gum, and dextrans.
  • the prebiotic is a combination of FOS having an average degree of polymerization of four and high performance inulin having an average degree of polymerization of twenty-five, wherein a weight ratio of the FOS to the high performance inulin is about 1 :1 .
  • a suitable commercially available prebiotic for use in the nutritional compositions and methods described herein is Synergyl ® high-performance inulin enriched with FOS (available from Beneo-Orafti S.A., Belgium).
  • Exemplary prebiotics that may be utilized in the nutritional compositions and methods described herein also include prebiotics selected from the group of oligosaccharides referred to as "human milk oligosaccharides".
  • Human milk oligosaccharides are one of the main components of human breast milk, which contains, on average, 10 grams per liter of neutral oligosaccharides and 1 gram per liter of acidic oligosaccharides.
  • the composition of human milk oligosaccharides is very complex and more than 200 different oligosaccharide- like structures are known.
  • HMOs that may be included individually or in combination in the nutritional compositions used in the methods of the present disclosure include: sialic acid (i.e., free sialic acid, lipid-bound sialic acid, protein-bound sialic acid); D-glucose (Glc); D-galactose (Gal); N-acetylglucosamine (GlcNAc); L-fucose (Fuc); fucosyl
  • oligosaccharides i.e., lacto-N-fucopentaose I; lacto-N-fucopentaose II; lacto-N- fucopentaose III; lacto-N-difucohexaose I; and lactodifucotetraose
  • lacto-N-fucopentaose I lacto-N-fucopentaose II
  • lacto-N- fucopentaose III lacto-N-difucohexaose I
  • lactodifucotetraose lactodifucotetraose
  • oligosaccharides i.e., lacto-N-tetraose
  • sialyl oligosaccharides i.e., 3'-sialyl-3- fucosyllactose; disialomonofucosyllacto-N-neohexaose; monofucosylmonosialyllacto-N- octaose (sialyl Lea); sialyllacto-N-fucohexaose II; disialyllacto-N-fucopentaose II;
  • sialyl fucosyl oligosaccharides i.e., 2'- sialyllactose; 2-sialyllactosamine; 3'- sialyllactosamine; 6'-sialyllactosamine; sialyllacto-N- neotetraose c; monosialyllacto-N-hexaose; disialyllacto-N-hexaose I; monosialyllacto-N- neohexaose I; monosialyllacto-N-neohexaose II; disialyllacto-N-neohexaose; disialyllacto-N- tetraose; disialyllacto-N-hexaose II; sialyllacto-N-hexaose II; sialyllacto-N-he
  • glucose (Glc) at the reducing end is replaced by N-acetylglucosamine (e.g., 2'-fucosyl- N-acetylglucosamine (2'FLNac) is such a variant to 2'-fucosyllactose).
  • N-acetylglucosamine e.g., 2'-fucosyl- N-acetylglucosamine (2'FLNac) is such a variant to 2'-fucosyllactose.
  • HMOs lacto-N-fucopentaose V, lacto-N-hexaose, para-lacto-N-hexaose, lacto-N- neohexaose, para-lacto-N-neohexaose, monofucosyllacto-N-hexaose II, isomeric
  • fucosylated lacto-N-hexaose (1 ), isomeric fucosylated lacto-N-hexaose (3), isomeric fucosylated lacto-N-hexaose (2), difucosyl-para-lacto-N-neohexaose, difucosyl-para-lacto-N- hexaose, difucosyllacto-N-hexaose, lacto-N-neoocataose, para-lacto-N-octanose, iso-lacto- N-octaose, lacto-N-octaose, monofucosyllacto-neoocataose, monofucosyllacto-N-ocataose, difucosyllacto-N-octaose I, difucosyllacto-N-octaose II,
  • trifucosyllacto-N-octaose trifucosyl-iso-lacto-N-octaose, lacto-N-difuco-hexaose II, sialyl- lacto-N-tetraose a, sialyl-lacto-N-tetraose b, sialyl-lacto-N-tetraose c, sialyl-fucosyl-lacto-N- tetraose I, sialyl-fucosyl-lacto-N-tetraose II, and disialyl-lacto-N-tetraose, and combinations thereof.
  • the HMOs that may be included individually or in combination in the nutritional compositions used in the methods of the present disclosure are selected from the group consisting of: 6'-sialyllactose (6'SL); lacto-N-neotetraose (LNnT); 3'- fucosyllactose (3'FL); 3'-sialyllactose (3'SL); and 2'-fucosyl lactose (2'FL), preferably selected from the group consisting of: 6'-sialyllactose (6'SL); lacto-N-neotetraose (LNnT); and 2'-fucosyl lactose (2'FL), more preferably 2'-fucosyllactose (2'FL).
  • the HMO or HMOs may be isolated or enriched from milk(s) secreted by mammals including, but not limited to: human, bovine, ovine, porcine, or caprine species.
  • the HMOs may also be produced via microbial fermentation, enzymatic processes, chemical synthesis, or combinations thereof.
  • the prebiotic comprises from about 1 % to about 20% by weight of the nutritional composition. In certain exemplary embodiments, the total amount of prebiotic may be provided by one or multiple prebiotics, including any one or more of the prebiotics disclosed herein. In certain exemplary embodiments, the prebiotic comprises from about 1 % to about 15% by weight of the nutritional composition, including from about 5% to about 12%, from about 5% to about 10%, or from about 7% to about 10% by weight of the nutritional composition.
  • the nutritional composition is a liquid and the prebiotic is present in an amount from about 0.001 mg/ml to about 20 mg/ml, including from about 0.001 mg/mL to about 10 mg/mL, including from about 0.001 mg/mL to about 5 mg/mL, including from about 0.001 mg/mL to less than 2 mg/mL, and also including from about 0.01 mg/mL to about 20 mg/mL, including from about 0.01 mg/mL to less than 2 mg/mL.
  • the amount of prebiotic may be provided by one or multiple prebiotics including any one or more of the prebiotics disclosed herein, particularly one or multiple human milk oligosaccharides described herein, preferably wherein the one or multiple human milk oligosaccharides are selected from the group consisting of 6'-sialyllactose (6'SL), lacto-N-neotetraose (LNnT), 3'- fucosyllactose (3'FL), 3'-sialyllactose (3'SL), and 2'-fucosyllactose (2'FL), preferably 6'- sialyllactose (6'SL), lacto-N-neotetraose (LNnT) and 2'-fucosyllactose (2'FL).
  • 6'-sialyllactose (6'SL), lacto-N-neotetraose (LNnT) and 2'-fucosyllacto
  • the nutritional composition is a powder and the prebiotic is present in an amount from about 0.0005% to about 5% by weight of the powder, including from about 0.01 % to about 1 %, by weight of the powder.
  • the amount of prebiotic may be provided by one or multiple prebiotics including any one or more of the prebiotics disclosed herein, particularly one or multiple human milk oligosaccharides described herein, preferably wherein the one or multiple human milk oligosaccharides are selected from the group consisting of 6'-sialyllactose (6'SL), lacto-N-neotetraose (LNnT), 3'- fucosyllactose (3'FL), 3'- sialyllactose (3'SL), and 2'-fucosyllactose (2'FL), preferably 6'-sialyllactose (6'SL), lacto-N- neotetraose (LNnT) and 2'-fucosyllactos
  • the nutritional composition is a bar and the prebiotic is present in an amount from about 0.0005% to about 10% by weight of the bar, including from about 0.01 % to about 5%, by weight of the bar.
  • the amount of prebiotic may be provided by one or multiple prebiotics including any one or more of the prebiotics disclosed herein, particularly one or multiple human milk oligosaccharides described herein, preferably wherein the one or multiple human milk oligosaccharides are selected from the group consisting of 6'-sialyllactose (6'SL), lacto-N-neotetraose (LNnT), 3'- fucosyllactose (3'FL), 3'- sialyllactose (3'SL), and 2'-fucosyllactose (2'FL), preferably 6'-sialyllactose (6'SL), lacto-N- neotetraose (LNnT) and 2'-fucosyllactose (2
  • the exemplary nutritional compositions described herein may include at least one of a protein, a carbohydrate, and a fat.
  • the nutritional composition comprises a protein, a carbohydrate, and a fat.
  • the nutritional composition comprises a protein, a carbohydrate, and is substantially free of fat.
  • substantially free of fat refers to a nutritional composition containing less than 0.5%, including less than 0.1 %, fat by weight of the nutritional composition.
  • substantially free of fat may also refer to a nutritional composition that contains no added fat, although the nutritional composition may contain some amount of fat resulting from an added ingredient (e.g., a protein source that inherently has some fat).
  • the nutritional composition comprises from about 6 grams to about 50 grams of protein per serving of the nutritional composition. In certain exemplary embodiments, the nutritional composition comprises from about 6 grams to about 45 grams of protein per serving, including from about 10 grams to about 40 grams, from about 15 grams to about 35 grams, and also including from about 15 grams to about 25 grams of protein per serving of the nutritional composition. In certain exemplary embodiments, the nutritional composition comprises from about 5% to about 40% by weight protein, including from about 10% to about 30%, and also including from about 15% to about 25% by weight protein.
  • the protein present in the exemplary nutritional compositions described herein may be provided by one source of protein or multiple sources of protein, so long as the source of protein is suitable for use in oral nutritional compositions and is otherwise compatible with any other selected ingredients or features in the nutritional composition.
  • the protein present in the exemplary nutritional compositions may be provided by protein sources including, but not limited to, intact protein, hydrolyzed protein, and partially hydrolyzed protein, which may be derived from any known or otherwise suitable source such as milk (e.g., casein, whey), animal (e.g., meat, fish), cereal (e.g., rice, corn), vegetable (e.g., soy, potato, pea), and combinations thereof.
  • milk e.g., casein, whey
  • animal e.g., meat, fish
  • cereal e.g., rice, corn
  • vegetable e.g., soy, potato, pea
  • the protein present in the exemplary nutritional compositions described herein is provided by any one or more of the following protein sources: a whey protein concentrate, a whey protein isolate, a whey protein hydrolysate, an acid casein, a sodium caseinate, a calcium caseinate, a potassium caseinate, a casein hydrolysate, a milk protein concentrate, a milk protein isolate, a milk protein hydrolysate, nonfat dry milk, condensed skim milk, skim milk powder, a soy protein concentrate, a soy protein isolate, a soy protein hydrolysate, a pea protein concentrate, a pea protein isolate, a pea protein hydrolysate, a collagen protein, a collagen protein isolate, potato protein, insect protein, earthworm protein, rice protein, quinoa protein, legume protein, grain protein, and combinations thereof.
  • the nutritional composition comprises from about 15 grams to about 1 10 grams of carbohydrates per serving of the nutritional composition, and the prebiotic comprises from about 1 % to about 25% by weight of the total carbohydrates. In certain exemplary embodiments, the nutritional composition comprises from about 25 grams to about 90 grams of carbohydrates per serving, including from about 40 grams to about 65 grams, and also including from about 45 grams to about 55 grams of carbohydrates per serving of the nutritional composition. In certain exemplary embodiments, the prebiotic comprises from about 5% to about 20% by weight of the total carbohydrates, including from about 10% to about 15%, from about 5% to about 10%, and also including about 7.5% by weight of the total carbohydrates.
  • the nutritional composition comprises from about 10% to about 80% by weight carbohydrates, including from about 30% to about 60%, and also including from about 50% to about 70% by weight carbohydrates.
  • the carbohydrates present in the exemplary nutritional compositions described herein may be provided by one source of carbohydrates or multiple sources of carbohydrates, so long as the source of carbohydrates is suitable for use in oral nutritional compositions and is otherwise compatible with any other selected ingredients or features in the nutritional composition.
  • the carbohydrate, in addition to the prebiotic, present in the exemplary nutritional compositions may be provided by carbohydrate sources such as simple carbohydrates, complex carbohydrates, or variations or combinations thereof.
  • carbohydrate present in the exemplary nutritional compositions described herein is provided by any one or more of the following carbohydrate sources: maltodextrin, hydrolyzed starch, modified starch, cornstarch, glucose polymers, corn syrup, corn syrup solids, rice-derived carbohydrate, sucrose, glucose, fructose, lactose, high fructose corn syrup, honey, sugar alcohol, isomaltulose, sucromalt, gum arabic, sodium carboxymethyl cellulose, guar gum, citrus pectin, low methoxy pectin, high methoxy pectin, oat beta-glucan, barley beta-glucan, carrageenan, psyllium, oat hull fiber, pea hull fiber, soy hull fiber, soy coty
  • the nutritional composition comprises from about 0.5 grams to about 45 grams of fat per serving of the nutritional composition. In certain exemplary embodiments, where the nutritional composition includes fat, the nutritional composition comprises from about 2 grams to about 40 grams of fat per serving of the nutritional composition, including from about 5 grams to about 35 grams, from about 10 grams to about 30 grams, and from about 15 grams to about 25 grams of fat per serving of the nutritional composition. In certain exemplary embodiments, where the nutritional composition includes fat, the nutritional composition comprises from about 0.5% to about 30% by weight fat, including from about 1 % to about 25%, from about 5% to about 20%, or from about 10% to about 15% by weight fat. When present in the exemplary nutritional compositions described herein, the fat may be provided by one source of fat or multiple sources of fat, so long as the source of fat is suitable for use in oral nutritional compositions and is otherwise compatible with any other selected ingredients or features in the nutritional composition.
  • the fat may be derived from fat sources such as plants, animals, and combinations thereof.
  • the fat may be provided by any one or more of the following fat sources: coconut oil, fractionated coconut oil, soy oil, corn oil, olive oil, safflower oil, high oleic safflower oil, high gamma- linolenic acid (GLA) safflower oil, MCT (medium chain triglycerides) oil, sunflower oil, high oleic sunflower oil, palm oil, palm kernel oil, palm olein, canola oil, marine oil, cottonseed oil, eicosapentaenoic acid, docosahexaenoic acid, gamma-linolenic acid, algal oil, and combinations thereof.
  • the nutritional composition is formulated as a clear liquid having a pH of about 2.0 to about 5.0, and also having no more than about 0.5% fat by weight of the nutritional composition.
  • the limited amount of fat contributes to the desired clarity of the nutritional composition.
  • liquid nutritional compositions that are clear, or at least substantially translucent, are substantially free of fat.
  • certain exemplary embodiments of liquid nutritional compositions that have a desired acidic pH in the range of about 2.0 to 5.0 e.g., juices, fruit juices, fruit-flavored beverages
  • Liquid nutritional compositions that are both clear and have a pH ranging from about 2.0 to about 5.0 are also typically substantially free of fat.
  • the pH of the nutritional composition may be from about 2.5 to about 4.6, including a pH of about 3.0 to about 3.5.
  • the fat may be present as a result of being inherently present in another ingredient (e.g., a protein source).
  • the nutritional composition may also comprise optional components or ingredients that modify the physical, chemical, aesthetic, or processing characteristics of the nutritional composition, or serve as additional nutritional components.
  • optional ingredients are known or otherwise suitable for use in medical food or other nutritional products and may also be used in the exemplary nutritional compositions described herein, provided that such optional ingredients are safe for oral administration and are compatible with the essential and other ingredients in the selected product form.
  • optional ingredients include vitamins, minerals, preservatives, emulsifying agents, buffers, creatine, probiotics, anti-inflammatory agents, colorants, flavorants, thickening agents, stabilizers, lubricants, flowing or anti-caking agents, masking agents, and so forth.
  • the nutritional composition may comprise any of a variety of vitamins or related nutrients, non-limiting examples of which include vitamin A, vitamin E, vitamin D 2 , vitamin D 3 , vitamin A palmitate, vitamin E acetate, vitamin C palmitate (ascorbyl palmitate), vitamin K, thiamine, riboflavin, pyridoxine, vitamin B 12 , carotenoids (e.g., beta-carotene, zeaxanthin, lutein, lycopene), niacin, folic acid, pantothenic acid, biotin, vitamin C, choline, inositol, salts and derivatives thereof, and combinations thereof.
  • vitamins or related nutrients include vitamin A, vitamin E, vitamin D 2 , vitamin D 3 , vitamin A palmitate, vitamin E acetate, vitamin C palmitate (ascorbyl palmitate), vitamin K, thiamine, riboflavin, pyridoxine, vitamin B 12 , carotenoids (e.g., beta-carotene
  • the nutritional composition comprises any of a variety of minerals.
  • suitable minerals include, but are not limited to, calcium, selenium, potassium, iodine, phosphorus, magnesium, iron, zinc, manganese, copper, sodium, molybdenum, chromium, chloride, and combinations thereof.
  • the various exemplary embodiments of the nutritional compositions described herein may be prepared by any process or suitable method (now known or known in the future) for making a selected product form, such as a nutritional liquid or a nutritional powder. Many such techniques are known for any given product form, such as nutritional liquids or nutritional powders, and can readily be applied by one of ordinary skill in the art to the various exemplary embodiments of the nutritional composition described herein.
  • an exemplary liquid nutritional composition is prepared utilizing at least three separate slurries, including a protein-in-fat (PIF) slurry, a carbohydrate-mineral (CHO-MIN) slurry, and a protein-in-water (PIW) slurry.
  • the PIF slurry is formed by heating and mixing the selected oil (e.g., canola oil, corn oil, fish oil) and then adding an emulsifier (e.g., lecithin), fat soluble vitamins, and a portion of the total protein (e.g., milk protein concentrate) with continued heat and agitation.
  • the CHO-MIN slurry is formed by adding with heated agitation to water: prebiotic, minerals (e.g., potassium citrate, dipotassium phosphate, sodium citrate), trace and ultra trace minerals (TM/UTM premix), thickening or suspending agents (e.g., microcrystalline cellulose, gellan, carrageenan).
  • the resulting CHO-MIN slurry is held for 10 minutes with continued heat and agitation before adding additional minerals (e.g., potassium chloride, magnesium carbonate, potassium iodide), or carbohydrates (e.g., sucrose, corn syrup), or combinations thereof.
  • additional minerals e.g., potassium chloride, magnesium carbonate, potassium iodide
  • carbohydrates e.g., sucrose, corn syrup
  • the PIW slurry is formed by mixing with heat and agitation the remaining protein (e.g., sodium caseinate, soy protein concentrate) into water.
  • the three resulting slurries are blended together with heated agitation and the pH adjusted to the desired range (e.g., 6.6 to 7.0) after which the blended composition is subjected to high-temperature short-time (HTST) processing during which the blended composition is heat treated, emulsified, homogenized, and then allowed to cool.
  • HTST high-temperature short-time
  • Water soluble vitamins and ascorbic acid are added (if applicable)
  • the pH is again adjusted (if necessary)
  • flavorants are added, and any additional water can be added to adjust the solids content of the liquid nutritional composition to the desired range.
  • the liquid nutritional composition may be packaged and sterilized according to any suitable sterilization technique, such as aseptic, retort, or hot-fill sterilization.
  • a nutritional powder suitable for use in the exemplary methods described herein may be prepared by any collection of known or otherwise effective techniques suitable for making and formulating a nutritional powder.
  • the spray drying step may likewise include any spray drying technique that is known for or otherwise suitable for use in the production of nutritional powders.
  • Many different spray drying methods and techniques are known for use in the nutrition field, all of which are suitable for use in the manufacture of the nutritional powders described herein.
  • One method of preparing a nutritional powder comprises forming and homogenizing an aqueous slurry or liquid comprising predigested fat, and optionally protein, carbohydrate, and other sources of fat, and then spray drying the slurry or liquid to produce a nutritional powder.
  • the method may further comprise the step of spray drying, dry-blending, or otherwise adding additional nutritional or functional ingredients, including any one or more of the ingredients described herein, to the nutritional powder.
  • the exemplary methods of increasing endogenous production of HMB described herein include administering a nutritional composition comprising a prebiotic to a subject. Any of the embodiments of the nutritional composition described above may be utilized in the exemplary methods.
  • the nutritional composition comprising a prebiotic is administered to a subject, and consumption of the nutritional composition increases endogenous levels of HMB in the subject.
  • the subject is a human.
  • the human may be an infant, an adolescent, an adult, or an elderly adult.
  • the subject has a condition that promotes protein degradation, a loss of lean body mass, a decrease in muscle strength, and combinations thereof.
  • Such conditions include, but are not limited to, cachexia, cancer, end stage renal disease, chronic obstructive pulmonary disease (COPD), diabetes, and so forth.
  • COPD chronic obstructive pulmonary disease
  • the increase in endogenous levels of HMB as a result of consuming the nutritional composition comprising a prebiotic can treat these conditions by attenuating protein degradation, attenuating losses of lean body mass, attenuating decreases in muscle strength, and combinations thereof.
  • a method of increasing endogenous production of HMB in an offspring of a subject is provided.
  • the nutritional composition comprising a prebiotic is administered to a subject during gestation.
  • the nutritional composition comprising a prebiotic is administered to a subject who is pregnant.
  • Consumption of the nutritional composition comprising a prebiotic by the subject during gestation increases endogenous levels of HMB in the offspring in the womb of the subject.
  • consumption of the nutritional composition comprising the prebiotic by the subject during gestation exposes the developing offspring to beneficial bacterially derived metabolites such as SCFAs and HMB, which facilitates healthy in utero development of the offspring, particularly the gastrointestinal tract of the offspring.
  • a method of increasing endogenous production of HMB in an offspring of a subject includes administering the nutritional composition comprising a prebiotic to the subject following delivery of the offspring and during breastfeeding of the offspring. Consumption of the nutritional composition comprising a prebiotic by the subject during breastfeeding increases endogenous levels of HMB in the offspring. It is believed that consumption of the nutritional composition comprising a prebiotic by the subject following delivery and during breastfeeding results in the endogenous production of HMB that subsequently enters circulation and the breast milk, and the endogenously produced HMB is then transferred via the breast milk to the breastfeeding offspring to facilitate healthy development of the offspring.
  • the nutritional composition comprising a prebiotic is administered to a subject during gestation and is also administered to the subject following delivery of the offspring and during breastfeeding of the offspring.
  • the nutritional composition comprising a prebiotic is administered to the offspring from weaning through adolescence. In other words, the nutritional composition is administered directly to the offspring after breastfeeding of the offspring is discontinued.
  • through adolescence means for a period of time during adolescence, which could be, for example, one month, three months, six months, one year, two years, and so forth.
  • the nutritional composition comprising a prebiotic is administered orally to the subject.
  • the nutritional composition comprising a prebiotic is administered to the subject at least once daily.
  • the nutritional composition comprising a prebiotic is chronically administered to the subject.
  • the phrases "chronically administered,” “chronic administration,” and “chronically administering” as used herein refers to regular administration which is provided indefinitely or to regular administration for a significant period of time.
  • chronic administration can include regular administration for at least two weeks, regular administration for at least one month, regular administration for at least 6 weeks, regular administration for at least two months, regular administration for at least 3 months, regular administration for at least 4 months, regular administration for at least 5 months, regular administration for at least 6 months, or regular administration for at least 9 months.
  • chronic administration refers to regular administration for at least 1 year, regular administration for at least 1 .5 years, regular administration for at least 2 years, or regular administration for more than 2 years.
  • Regular administration refers to administration according to a schedule whereby the subject consumes the exemplary nutritional composition at regular intervals.
  • administration at regular intervals refers to administration in a repeating, periodic fashion where the time between administrations is approximately (or intended to be approximately) the same.
  • administration at regular intervals includes daily administration or weekly administration.
  • administration at regular intervals includes administration 1-2 times per week, administration 1 -3 times per week, administration 2-3 times per week, administration 1-4 times per week, administration 1-5 times per week, administration 2-5 times per week, administration 3-5 times per week, administration 1-6 times per week, administration 1-7 times per week, administration 2-6 times per week, administration 2-7 times per week, administration 1-2 times per day, administration 1 -3 times per day, administration 1-4 times per day, administration 2-3 times per day, administration 2-4 times per day, administration 3-4 times per day, administration 2-5 times per day, administration 3-5 times per day, or administration 4-5 times per day.
  • the consumption takes place every day for: at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months during gestation, or in some instances daily during the entire period of gestation.
  • the exemplary methods are intended to encompass consumption of the nutritional composition comprising a prebiotic on less than every day of the period of pregnancy or gestation.
  • the nutritional composition comprising a prebiotic is consumed by the subject on at least 1 day per week, at least 2 days per week, at least 3 days per week, at least 4 days per week, at least 5 days per week, or at least 6 days per week during gestation.
  • This periodic consumption may take place for: at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months during gestation or in some instances during the entire period of gestation.
  • the nutritional composition comprising a prebiotic is consumed daily by the subject following delivery of the offspring and during breastfeeding of the offspring.
  • the consumption takes place every day for: at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 9 months, at least 12 months, at least 18 months, and up to the period of time when the offspring is weaned. It should be understood that the exemplary methods are intended to encompass consumption of the nutritional composition comprising a prebiotic on less than every day following delivery of the offspring and during breastfeeding of the offspring.
  • the nutritional composition comprising a prebiotic is consumed by the subject on at least 1 day per week, at least 2 days per week, at least 3 days per week, at least 4 days per week, at least 5 days per week or at least 6 days per week following delivery and during breastfeeding of the offspring.
  • This periodic consumption may take place for: at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 9 months, at least 12 months, at least 18 months, and up to 24 months or up to the period of time when the offspring is weaned (i.e., the entire period of time when the subject breastfeeds the offspring).
  • the nutritional composition comprising a prebiotic is consumed daily by the subject during gestation and also following delivery and during breastfeeding of the offspring.
  • the consumption takes place every day for: at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months during gestation or in some instances daily during the entire period of gestation.
  • the exemplary methods are intended to encompass consumption of the nutritional composition comprising a prebiotic on less than every day during gestation and on less than every day during breastfeeding of the offspring.
  • the nutritional composition comprising a prebiotic is consumed by the subject on at least 1 day per week, at least 2 days per week, at least 3 days per week, at least 4 days per week, at least 5 days per week, or at least 6 days per week during gestation and during breastfeeding of the offspring.
  • This periodic consumption may take place for: at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months during gestation or in some instances during the entire period of gestation.
  • the periodic consumption described may take place during similar periods or during the entire period of breastfeeding the offspring. It should be understood that the schedule of administration or consumption during the period of gestation may be the same or different than the schedule of administration or consumption during the period of breastfeeding the offspring.
  • the nutritional composition comprising a prebiotic is administered such that the amount of prebiotic consumed by the subject ranges from about 0.001 g/day to about 15 g/day, including from about 0.001 g/day to about 10 g/day, and including from about 0.1 g/day to about 5 g/day.
  • the nutritional composition comprising a prebiotic is provided in one or multiple (e.g., two, three, four) servings per day to achieve the desired amount of prebiotic.
  • the nutritional composition comprising a prebiotic is provided in two servings per day to achieve the desired amount of prebiotic.
  • administration of a nutritional composition comprising a prebiotic may result in a chronic increase in endogenous HMB production such that HMB levels remain elevated for a sustained period.
  • the nutritional composition may be chronically administered according to any of the embodiments described above.
  • the one or more prebiotics of the composition may be selected from short chain fructooligosaccharides (FOS), long chain FOS, inulins, galactooligosaccharides (GOS), xylooligosaccharides (XOS), resistant starch, and combinations thereof.
  • administration of a nutritional composition comprising a prebiotic may result in an acute increase in endogenous HMB production such that HMB levels are elevated rapidly, typically after a single administration of composition.
  • acute increase may be taken to mean an increase in endogenous HMB production occurring within a time period directly after administration of the composition of approximately 1 hour, approximately 2 hours, approximately 3 hours, or a time period up to 5 hours (300 minutes) after administration.
  • the one or more prebiotics of the composition may be human milk oligosaccharides selected from: 6'-sialyllactose (6'SL); lacto-N-neotetraose (LNnT); 3'- fucosyllactose (3'FL); 3'-sialyllactose (3'SL); and 2'-fucosyllactose (2'FL), preferably selected from the group consisting of: 6'- sialyllactose (6'SL); lacto-N-neotetraose (LNnT); and 2'-fucosyllactose (2'FL), more preferably 2'-fucosyllactose (2'FL).
  • 6'-sialyllactose (6'SL); lacto-N-neotetraose (LNnT); 3'-sialyllactose (3'SL); and 2'-fucosyllactose (2'FL
  • the level of endogenous HMB in a subject may be determined by a variety of suitable methods (now known or known in the future).
  • the level of HMB in the serum and urine of a subject can be determined by ultra-high performance liquid chromatography- tandem mass spectrometry (UHPLC-MS/MS).
  • UHPLC-MS/MS ultra-high performance liquid chromatography- tandem mass spectrometry
  • a first measurement of endogenous HMB may be obtained from the subject within 1 week prior to initiation of the administration of the nutritional composition comprising a prebiotic disclosed herein. The first measurement may take place within 1 day to 7 days prior to initiation of the administration.
  • a second measurement of endogenous HMB may be obtained from the subject.
  • the second measurement may be obtained within a few hours after administration of the nutritional composition, for example within 8 hours, within 5 hours. Alternatively or in addition, the second measurement may be obtained at least two weeks after administration of the nutritional composition comprising a prebiotic has commenced, including at least one month, at least three months, at least six months, or at least one year after administration of the nutritional composition comprising a prebiotic has commenced.
  • the second measurement of endogenous HMB is compared to the first measurement of endogenous HMB to determine the amount of increase in the endogenous production of HMB in the subject.
  • the endogenous levels of HMB in the subject may increase at least 5%, including at least 9%, including at least 15%, including at least 25%, including at least 35%, including at least 40%, including at least 50% or more as a result of consuming a nutritional composition comprising a prebiotic as described herein.
  • HMB has previously been recognized as an important metabolite, and compositions containing HMB as a dietary supplement have been described for a variety of applications linked to the control of skeletal muscle metabolism, glucose metabolism, brain development and cognitive function, see for example International patent applications: WO2012/092035, WO2012/097061 , WO2012/097064 and WO2012/1 12419, the contents of which are incorporated herein in their entirety.
  • WO2012/092035 WO2012/097061 , WO2012/097064 and WO2012/1 12419, the contents of which are incorporated herein in their entirety.
  • prebiotics are able to increase endogenous production of HMB gives rise to the possibility of using nutritional compositions comprising prebiotics in situations where increased HMB levels are desirable or have therapeutic benefit.
  • compositions comprising a prebiotic for use in promoting muscle hypertrophy and/or preventing muscle atrophy in a subject.
  • muscle hypertrophy means the increase in the size or mass of one or more skeletal muscles as a consequence of muscle cell growth.
  • muscle atrophy is used herein to mean the opposite of muscle hypertrophy i.e. a decrease in the size or mass of one or more skeletal muscles.
  • Muscle atrophy is typically caused by a change in the normal balance between protein synthesis and protein degradation in favour of destructive protein pathways.
  • the "promotion" of muscle hypertrophy may be measured or determined by an increase in muscle mass over a defined period of time and the "prevention" of muscle atrophy may be measured or determined by the absence of a decrease in muscle mass over a defined period of time.
  • the methods of promoting muscle hypertrophy and/or preventing muscle atrophy involve administering a nutritional composition comprising a prebiotic to a healthy individual i.e. an individual who is not affected by a disease condition and in particular an individual who is not affected by a disease condition affecting skeletal muscle.
  • a healthy individual i.e. an individual who is not affected by a disease condition and in particular an individual who is not affected by a disease condition affecting skeletal muscle.
  • the nutritional compositions described herein are administered to healthy adult subjects to promote muscle hypertrophy and/or prevent muscle atrophy.
  • Such methods may be performed for the purposes of increasing muscle strength and/or performance and/or for the purposes of regulating or maintaining lean body mass.
  • the methods described herein as applied to healthy subjects may be regarded as non-therapeutic methods of promoting muscle hypertrophy and/or preventing muscle atrophy.
  • the methods of promoting muscle hypertrophy and/or preventing muscle atrophy involve administering a nutritional composition comprising a prebiotic to a subject having muscle atrophy caused by a period of muscle disuse, for example an extended period of muscle disuse consisting of at least four weeks, at least six weeks, at least six months or at least one year.
  • the period of muscle disuse may be caused by immobilization of a part of the body, for example the immobilization of a broken limb in a cast, or may be caused by an extended period of enforced bedrest. It will be recognized by one skilled in the art that the rate of muscle atrophy for individuals may differ on the basis of, for example, age; that is elderly adults may experience more rapid muscle atrophy as compared with adolescents.
  • the methods of promoting muscle hypertrophy and/or preventing muscle atrophy involve administering a nutritional composition comprising a prebiotic to a subject having cachexia, particularly wherein the cachexia is a co-morbidity of a disease or condition selected from cancer, congestive heart failure, chronic obstructive pulmonary disease (COPD) and/or liver failure.
  • a nutritional composition comprising a prebiotic to a subject having cachexia, particularly wherein the cachexia is a co-morbidity of a disease or condition selected from cancer, congestive heart failure, chronic obstructive pulmonary disease (COPD) and/or liver failure.
  • COPD chronic obstructive pulmonary disease
  • compositions comprising a prebiotic for use in improving brain development and/or cognitive function in a subject.
  • the nutritional composition is administered to a subject selected from an infant, a toddler, a child, an adolescent or an elderly adult as defined elsewhere herein.
  • the method is carried out by administration of nutritional composition comprising a prebiotic to an infant, toddler, child or adolescent who is otherwise healthy i.e. is not affected by a disease condition, particularly an infant or adolescent who is not affected by a condition affecting the brain and/or cognition.
  • the nutritional composition is administered to improve brain development and/or cognitive function in said infant or adolescent.
  • brain development means the growth, maturation and remodeling of neurons that occurs in the brain, particularly in infants and adolescents.
  • An improvement in brain development may be measured or determined by an improvement in the mental performance of a subject, as assessed by standard tests routinely carried out to gauge mental performance.
  • the term “cognitive function” means the level of cognition displayed by a given individual. By “cognition” is meant the mental processes involved in gaining knowledge and comprehension, including thinking, knowing,
  • cognition includes higher-level functions of the brain and encompasses language, imagination, perception, and planning.
  • An improvement in "cognitive function" may be measured or determined by an improvement in the cognition of a subject, as assessed by standard tests routinely used to test the various mental skills falling under the term cognition as defined above.
  • Improvements in brain development and/or cognitive function may be determined over a defined period of time and/or may be compared to any improvement determined for one or more control subjects, particularly wherein the control subjects do not receive a nutritional composition comprising prebiotic.
  • methods of improving brain development and/or cognitive function are carried out by administration of a nutritional composition comprising a prebiotic to a preterm infant.
  • preterm infant refers to a person born prior to 36 weeks of gestation.
  • the method may be carried out to improve brain development and/or cognitive function such that the preterm infant, when assessed using standard tests for cognition, performs at the standard expected of an average term infant at the same age.
  • methods of improving brain development and/or cognitive function are carried out by administration of a nutritional composition comprising a prebiotic to an elderly subject, optionally wherein the elderly adult is determined to be risk of cognitive decline or is already diagnosed as having cognitive impairment.
  • a neurodegenerative disorder for example a neurodegenerative disorder selected from Alzheimer's disease, Huntington's disease, Parkinson's disease, dementia, amyotrophic lateral sclerosis, stroke and schizophrenia.
  • methods of preventing or treating a disease or condition selected from sarcopenia, muscle wasting diseases, hyperglycaemia, glucose intolerance and neurodegenerative diseases comprising administering a nutritional composition comprising a prebiotic to a subject.
  • compositions comprising a prebiotic for use in preventing or treating a disease or condition selected from sarcopenia, muscle wasting diseases, hyperglycaemia, glucose intolerance and neurodegenerative diseases.
  • Sarcopenia is the term typically used to describe the degenerative loss of skeletal muscle mass and strength associated with aging. It is a condition that is typically not caused by or associated with other pathological conditions and therefore can affect otherwise healthy individuals.
  • methods of preventing or treating sarcopenia involve administering a composition comprising a prebiotic to an elderly subject who is otherwise healthy, particularly an elderly subject who does not suffer from any other muscle-wasting disease or condition.
  • cachexia is a term used to describe the muscle wasting that occurs in individuals suffering from a number of different diseases.
  • HAV/AIDS human immunodeficiency virus/acquired immune deficiency syndrome
  • COPD chronic obstructive pulmonary disease
  • ESRD end stage renal disease
  • tuberculosis congestive heart failure and familial amyloid polyneuropathy.
  • hyperglycaemia means high blood glucose levels, typically a blood glucose level of higher than 1 1.1 mmol/l (200 mg/dl). Hyperglycaemia is the characteristic defining individuals having the condition "glucose intolerance". Both hyperglycaemia and glucose intolerance are metabolic defects associated with a number of diseases. Thus, in certain embodiments, provided herein are methods for preventing or treating the hyperglycaemia and/or glucose intolerance in subjects suffering from a disease selected from COPD, obesity, diabetes and cancer.
  • a neurodegenerative disease optionally wherein the neurodegenerative disease is selected from Alzheimer's disease, Huntington's disease, Parkinson's disease, dementia, amyotrophic lateral sclerosis, stroke and schizophrenia.
  • the "prevention" of a neurodegenerative disease may involve preventing the onset of clinical symptoms typically associated with the disease, for example, the onset of clinical dementia.
  • Methods for the "treatment" of neurodegenerative disease may include methods intended to alleviate symptoms of disease or methods that are aimed at stabilizing or reversing the underlying pathology.
  • the methods of preventing neurodegenerative disease as described herein may involve administering a composition comprising a prebiotic to a subject identified as "at risk” of disease, wherein a subject "at risk” is one identified as having a higher probability of developing the disease as compared with an average individual in the general population, or a given population.
  • the methods of treating neurodegenerative disease as described herein may involve administering a composition comprising a prebiotic to any individual diagnosed as having the neurodegenerative disease.
  • the nutritional compositions for use in any of the methods described herein can include any features or combination of features described herein.
  • the nutritional composition is administered to the subject at a dose effective to produce an increase in HMB production in said subject.
  • the increase in HMB production may be measured as an increase in endogenous HMB levels, optionally endogenous plasma HMB levels, optionally wherein the increase in endogenous HMB levels is an increase of at least 5%, at least 10%, at least 25%, at least 50%.
  • a method of increasing endogenous production of beta-hydroxy-beta-methylbutyrate in a subject comprising:
  • a nutritional composition comprising a prebiotic to the subject, whereby consumption of the nutritional composition increases endogenous levels of beta-hydroxy- beta methylbutyrate in the subject.
  • galactooligosaccharides galactooligosaccharides, xylooligosaccharides, resistant starch, and combinations thereof.
  • fructooligosaccharides to the high performance inulin is about 1 :1 .
  • the nutritional composition further comprises at least one of a protein, a carbohydrate, and a fat.
  • the nutritional composition comprises from about 6 grams to about 50 grams of protein per serving.
  • the protein is one of a whey protein concentrate, a whey protein isolate, a whey protein hydrolysate, an acid casein, a sodium caseinate, a calcium caseinate, a potassium caseinate, a casein hydrolysate, a milk protein concentrate, a milk protein isolate, a milk protein hydrolysate, nonfat dry milk, condensed skim milk, skim milk powder, a soy protein concentrate, a soy protein isolate, a soy protein hydrolysate, a pea protein concentrate, a pea protein isolate, a pea protein hydrolysate, a collagen protein, collagen protein isolates, potato protein, insect protein, earthworm protein, rice protein, quinoa protein, legume protein, grain protein, and combinations thereof.
  • the nutritional composition comprises from about 15 grams to about 1 10 grams of carbohydrates per serving, and wherein the prebiotic comprises from about 1 % to about 25% by weight of the total carbohydrates.
  • the carbohydrate is one of maltodextrin, hydrolyzed starch, modified starch, cornstarch, glucose polymers, corn syrup, corn syrup solids, rice-derived carbohydrate, sucrose, glucose, fructose, lactose, high fructose corn syrup, honey, sugar alcohol, isomaltulose, sucromalt, gum arabic, sodium carboxymethyl cellulose, guar gum, citrus pectin, low methoxy pectin, high methoxy pectin, oat beta-glucan, barley beta-glucan, carrageenan, psyllium, oat hull fiber, pea hull fiber, soy hull fiber, soy cotyledon fiber, sugar beet fiber,
  • the fat is one of coconut oil, fractionated coconut oil, soy oil, corn oil, olive oil, safflower oil, high oleic safflower oil, high gamma-linolenic acid (GLA) safflower oil, MCT (medium chain triglycerides) oil, sunflower oil, high oleic sunflower oil, palm oil, palm kernel oil, palm olein, canola oil, marine oil, cottonseed oil, eicosapentaenoic acid, docosahexaenoic acid, gamma-linolenic acid, algal
  • a nutritional composition comprising a prebiotic to the subject during gestation, whereby consumption of the nutritional composition by the subject during gestation increases endogenous levels of beta-hydroxy-beta methylbutyrate in the offspring in the womb.
  • a method of increasing endogenous production of beta-hydroxy-beta-methylbutyrate in an offspring of a subject comprising:
  • a nutritional composition comprising a prebiotic to the subject following delivery of the offspring and during breastfeeding of the offspring, whereby consumption of the nutritional composition by the subject during breastfeeding of the offspring increases endogenous levels of beta-hydroxy-beta methylbutyrate in the offspring.
  • fructooligosaccharides having an average degree of polymerization of 4 and high
  • the nutritional composition further comprises at least one of a protein, a carbohydrate, and a fat.
  • the nutritional composition comprises from about 6 grams to about 50 grams of protein per serving.
  • the protein is one of a whey protein concentrate, a whey protein isolate, a whey protein hydrolysate, an acid casein, a sodium caseinate, a calcium caseinate, a potassium caseinate, a casein hydrolysate, a milk protein concentrate, a milk protein isolate, a milk protein hydrolysate, nonfat dry milk, condensed skim milk, skim milk powder, a soy protein concentrate, a soy protein isolate, a soy protein hydrolysate, a pea protein concentrate, a pea protein isolate, a pea protein hydrolysate, a collagen protein, collagen protein isolates, potato protein, insect protein, earthworm protein, rice protein, quinoa protein, legume protein, grain protein, and combinations thereof. 28. The method of any one of clauses 25-27, wherein the nutritional composition from about 15 grams to about
  • the fat is one of coconut oil, fractionated coconut oil, soy oil, corn oil, olive oil, safflower oil, high oleic safflower oil, high gamma-linolenic acid (GLA) safflower oil, MCT (medium chain triglycerides) oil, sunflower oil, high oleic sunflower oil, palm oil, palm kernel oil, palm olein, canola oil, marine oil, cottonseed oil, eicosapentaenoic acid, docosahexaenoic acid, gamma-linolenic acid, algal oil, and combinations thereof.
  • GLA gamma-linolenic acid
  • a nutritional composition comprising a prebiotic for use in increasing endogenous production of beta-hydroxy-beta-methylbutyrate in a subject.
  • a nutritional composition comprising a prebiotic for use in increasing endogenous production of beta-hydroxy-beta-methylbutyrate in an offspring of a subject, wherein consumption of the nutritional composition by the subject during gestation increases endogenous levels of beta-hydroxy-beta methylbutyrate in the offspring in the womb.
  • a nutritional composition comprising a prebiotic for use in increasing endogenous production of beta-hydroxy-beta-methylbutyrate in an offspring of a subject, whereby consumption of the nutritional composition by the subject following delivery and during breastfeeding of the offspring increases endogenous levels of beta-hydroxy-beta methylbutyrate in the offspring.
  • fructooligosaccharides inulins, galactooligosaccharides, xylooligosaccharides, resistant starch, and combinations thereof.
  • composition of any one of clauses 35-41 wherein the prebiotic comprises fructooligosaccharides having an average degree of polymerization of 4 and high performance inulin having an average degree of polymerization of 25, and wherein a weight ratio of the fructooligosaccharides to the high performance inulin is about 1 :1 .
  • composition of clause 44, wherein the nutritional composition comprises from about 6 grams to about 50 grams of protein per serving.
  • composition of clause 44 or 45 wherein the protein is one of a whey protein concentrate, a whey protein isolate, a whey protein hydrolysate, an acid casein, a sodium caseinate, a calcium caseinate, a potassium caseinate, a casein hydrolysate, a milk protein concentrate, a milk protein isolate, a milk protein hydrolysate, nonfat dry milk, condensed skim milk, skim milk powder, a soy protein concentrate, a soy protein isolate, a soy protein hydrolysate, a pea protein concentrate, a pea protein isolate, a pea protein hydrolysate, a collagen protein, collagen protein isolates, potato protein, insect protein, earthworm protein, rice protein, quinoa protein, legume protein, grain protein, and combinations thereof.
  • the protein is one of a whey protein concentrate, a whey protein isolate, a whey protein hydrolysate, an acid casein, a sodium caseinate, a calcium caseinate, a potassium caseinate,
  • the carbohydrate is one of maltodextrin, hydrolyzed starch, modified starch, cornstarch, glucose polymers, corn syrup, corn syrup solids, rice-
  • composition of any one of clauses 44 to 48, wherein the nutritional composition comprises from about 0.5 grams to about 45 grams of fat per serving.
  • the fat is one of coconut oil, fractionated coconut oil, soy oil, corn oil, olive oil, safflower oil, high oleic safflower oil, high gamma-linolenic acid (GLA) safflower oil, MCT (medium chain triglycerides)
  • composition of any one of claims 35 to 50, wherein the nutritional composition is one of a liquid, a liquid reconstituted from a powder, and a solid.
  • the nutritional composition is an emulsion.
  • Example 1 describes an animal study that was conducted to determine the effect of prebiotic supplementation of growing Sprague-Dawley rats as a nutritional approach to improve the health, particularly the bone health, of the rats. It was unexpectedly discovered that the rats that received prebiotic supplementation had significantly higher levels of HMB in the plasma and urine as compared to the rats that did not receive prebiotic supplementation.
  • mice Twenty five day-old Sprague-Dawley rats (Charles Rivers Laboratories, Louisiana Cedex, France) were housed in groups of four per cage under standardized environmental conditions (22 °C, relative humidity of 50%, artificial lighting on for 12 hours/day) and were given free access to de-ionized water during the study period.
  • the prebiotic is a 1 :1 mixture of fructooligosaccharides with an average degree of polymerization (DP) of 4 and high performance inulin with an average DP of 25.
  • the rats were individualized.
  • the Control group rats were fed with a purified rodent diet (AIN-93M) and the Prebiotic group rats were fed with a purified rodent diet (AIN-93G) containing 7.5% (w/w) of the total carbohydrates as inulin-type fructans (Synergy-1TM, Orafti, Belgium). Both the Control group rats and the Prebiotic group rats were fed their respective diet until the end of their adolescence period (90 days).
  • HMB can be endogenously produced by a pathway associated with prebiotic fermentation in the bowel by intestinal microbiota.
  • the HMB endogenously produced via prebiotic fermentation by intestinal microbiota could be easily absorbed by enterocytes and reach the blood circulation to contribute to the final concentration of HMB in the serum.
  • the urine samples collected were also analyzed for HMB concentration under non-fasting conditions over a four day period. It is estimated that approximately 40% of circulating HMB is eliminated through the urine, and that the concentration of HMB in the urine is directly dependent on the daily physiological kinetics of HMB. Accordingly, a higher amount of HMB excreted in the urine would be directly associated with higher concentrations of HMB in the plasma as a consequence of either an increase in the endogenous production of HMB or the exogenous consumption of HMB. As can be determined from Table 1 , the Prebiotic group rats excreted 75% more HMB through the urine as compared to the Control group rats.
  • HMB excretion by the Prebiotic group was calculated by considering the absolute amount of HMB ⁇ g) excreted in the urine over a four day collection period and is expressed as a percentage change with respect to the Control group. Since neither the Prebiotic group rat diet nor the Control group rat diet included HMB, the data suggests that consumption of prebiotics may increase endogenous production of HMB via microbiota fermentation of the prebiotics.
  • Example 2 describes an animal study that was conducted to determine the effect of prebiotic supplementation of Sprague-Dawley rat dams during their gestation and lactation periods as a nutritional approach to improve the health, particularly the bone health, of the offspring. It was unexpectedly discovered that the offspring of rat dams that received prebiotic supplementation had significantly higher levels of HMB in the plasma and urine as compared to the offspring of rat dams that did not receive prebiotic supplementation.
  • the prebiotic is a 1 :1 mixture of fructooligosaccharides with an average degree of polymerization (DP) of 4 and high performance inulin with an average DP of 25. All rat dams were fed their respective diet ad libitum during the periods of gestation and lactation.
  • offspring were separated from the dams and were housed in groups of four offspring per cage. Forty-three days after delivery, the offspring were individualized. During the period from weaning until the end of adolescence (90 days), the offspring of the Control group were fed with a purified rodent diet (AIN-93M) and the offspring of the Prebiotic group were fed with a purified rodent diet (AIN-93M) containing 7.5% (w/w) of the total carbohydrates as inulin-type fructans (Synergy-1TM, Orafti, Belgium).
  • the offspring were housed in metabolic cages over a four day period and urine samples were collected in acidified tubes under postprandial condition. Subsequently, the offspring were sacrificed after overnight fasting. Blood samples from the offspring were obtained by cardiac puncture. Serum was isolated, frozen, and stored at -80 °C until analysis. The level of HMB in the serum and urine samples was determined by ultra high-performance liquid chromatography - tandem mass spectrometry (UHPLC-MS/MS). Statistical Analysis - The data presented in Table 2 are expressed as means ⁇ standard error of the mean (SEM) of up to eight measurements. To evaluate the differences in the means between the Control group and the Prebiotic group, t-test or Mann-Whitney non- parametric test, when variance was not homogenously distributed, were performed.
  • HMB can be endogenously produced by a pathway associated with prebiotic fermentation in the bowel by intestinal microbiota.
  • the HMB endogenously produced via prebiotic fermentation by intestinal microbiota could be easily absorbed by enterocytes and contribute to the final concentration of HMB in the blood circulation.
  • urine samples were also analyzed for HMB concentration under non-fasting conditions.
  • the Prebiotic group offspring had a significantly higher level of HMB in urine as compared to the Control group offspring. Since neither the Prebiotic group offspring diet nor the Control group offspring diet included HMB, the data suggests that consumption of prebiotic by the rat dams during gestation and lactation, as well as consumption of prebiotic by the offspring, may exert a beneficial effect on the offspring microbiota that results in an accumulative increase in the endogenous production of HMB. Accordingly, the data suggests that prebiotics may be used as an alternative source of HMB.
  • Examples 3-5 illustrate exemplary embodiments of a nutritional composition in the form of a nutritional powder and formulated for consumption by a pregnant woman or a lactating woman.
  • the nutritional powder may be prepared by spray drying methods or dry blending, and may be reconstituted with water prior to use to the desired target ingredient concentrations. All ingredient amounts are listed as kilogram per 1000 kilogram batch of product, unless otherwise specified.
  • Example 6 illustrates an exemplary embodiment of a nutritional composition formulated as a nutritional powder.
  • the nutritional powder may be prepared by spray drying methods or dry blending, and may be reconstituted with water prior to use to the desired target ingredient concentrations. All ingredient amounts are approximate and listed as kilogram per 1000 kilogram batch of product, unless otherwise specified.
  • Vitamin ADEK Premix 105.0 g dl-Alpha Tocopheryl Acetate 30.4 g
  • Example 7 illustrates an exemplary embodiment of a nutritional composition formulated as a nutritional liquid.
  • the nutritional liquid may be prepared according to any of a variety of manufacturing processes, including those described herein. All ingredient amounts are approximate and listed as kilogram per 1000 kilogram batch of product, unless otherwise specified.
  • Vitamin Premix (water soluble) 68.6 g
  • Vitamin A Palmitate (55% in Vegetable 8.4 g
  • Example 8 describes an animal study that was conducted to determine the effect of human milk oligosaccharide (HMO) supplementation on growing Sprague-Dawley rats.
  • the protocol for this experimental procedure was carried out according to ethical guidelines for animal experimentation at the Spanish National Research Council (RD 53/2013). It was unexpectedly discovered that the rats that received HMO supplementation had significantly higher levels of HMB in the plasma and urine as compared to the rats that did not receive HMO supplementation.
  • HMB levels Prior to intragastric gavage, a blood sample was taken from the rats in each group. This was used to determine basal HMB levels at time zero (Time 0 or TO). Repeated blood samples were taken at 30, 60, 90, 120, 180, 240 and 300 minutes after the gavage. Serum was obtained and stored frozen for subsequent analysis. Urine samples were also collected at TO and at 300 minutes post gavage (T300). HMB levels were determined in both serum and urine samples by ultra-high-performance-liquid-chromatography-tandem mass spectrometry (UHPLC-MS/MS).
  • UHPLC-MS/MS ultra-high-performance-liquid-chromatography-tandem mass spectrometry
  • HMB concentration was measured in urine samples taken from the rats pre- and post- gavage. As shown in Figure 3, around 300 minutes after gavage, the rats excreted a significantly higher amount of HMB as compared with the amount of HMB excreted at baseline.
  • compositions for use according to the methods of the invention. These exemplified compositions, unless otherwise specified, includes an aseptically processed embodiment and a retort packaged embodiment.
  • Soybean oil 10.6 10.6 10.6 10.6
  • Tricalcium phosphate 15.65 g 15.65 g 15.65 g 15.65 g 15.65 g 15.65 g 15.65 g
  • Examples 14-18 Prophetic examples 14-18 illustrate ready-to-feed nutritional emulsions of the present disclosure, the ingredients of which are listed in the table below. All ingredient amounts listed are in kilograms, unless otherwise specified. Table 4: Examples 14-18
  • Examples 39-43 Prophetic examples 39-43 illustrate spray dried nutritional powders, the ingredients of which are listed in the table below. All ingredient amounts listed are in kilograms, unless otherwise specified. Table 9: Examples 39-43
  • Acesulfame Potassium 76.0 g 76.0 g 76.0 g 76.0 g 76.0 g dl-Alpha-Tocopheryl Acetate 54.5 g 54.5 g 54.5 g 54.5 g 54.5 g 54.5 g
  • Vitamin D3 13.2 mg 13.2 mg 13.2 mg 13.2 mg 13.2 mg
  • Vitamin A Palmitate 4.5 g 4.5 g 4.5 g 4.5 g 4.5 g 4.5 g 4.5 g
  • Prophetic examples 54-58 illustrate liquid formulations, the ingredients of which are listed in the table below. All ingredient amounts listed are in kilograms, unless otherwise specified.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Pediatric Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention concerne des compositions nutritionnelles et des procédés d'augmentation de la production endogène de bêta-hydroxy-bêta-méthylbutyrate chez un sujet. Les procédés comprennent l'administration d'une composition nutritionnelle comprenant un prébiotique à un sujet. Le prébiotique peut comprendre un ou plusieurs fructo-oligosaccharides à chaîne courte, fructo-oligosaccharides à chaîne longue, galactooligosaccharides, xylooligosaccharides, inulines, et amidons résistants ou peut être un oligosaccharide de lait humain, éventuellement choisi parmi 6'-sialyllactose (6'SL), lacto-N-néotétraose (LNnT), 3'-fucosyllactose (3'FL), et 3 '-sialyllactose (3'SL), et 2'-fucosyllactose (2'FL).
PCT/US2015/046292 2014-08-22 2015-08-21 Procédés d'augmentation de la production endogène de bêta-hydroxy-bêta-méthylbutyrate Ceased WO2016029113A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14382323 2014-08-22
EP14382323.5 2014-08-22

Publications (1)

Publication Number Publication Date
WO2016029113A1 true WO2016029113A1 (fr) 2016-02-25

Family

ID=51485538

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/046292 Ceased WO2016029113A1 (fr) 2014-08-22 2015-08-21 Procédés d'augmentation de la production endogène de bêta-hydroxy-bêta-méthylbutyrate

Country Status (1)

Country Link
WO (1) WO2016029113A1 (fr)

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107280012A (zh) * 2016-03-30 2017-10-24 邢亮 一种具有心血管调理作用的食疗产品及其制备方法
WO2018020473A1 (fr) * 2016-07-28 2018-02-01 Fonterra Co-Operative Group Limited Produit laitier et procédé associé
US10485253B2 (en) 2017-08-21 2019-11-26 Mustapha Benmoussa Method of microalgal biomass processing for high-value chemicals production, the resulting composition of butyrogenic algal slowly fermenting dietary fiber, and a way to improve colon health using a slowly fermenting butyrogenic algal dietary fiber
WO2019071021A3 (fr) * 2017-10-04 2020-04-02 The Regents Of The University Of California Oligosaccharides immunomodulateurs
CN111248289A (zh) * 2018-11-30 2020-06-09 内蒙古伊利实业集团股份有限公司 一种组合物、其制备方法及用途
WO2021048440A1 (fr) * 2019-09-13 2021-03-18 Basf Se Composition pour le traitement de maladies neurodégénératives
WO2021123253A1 (fr) * 2019-12-19 2021-06-24 Basf Se Composition pour le traitement de la (pré)hyperglycémie et/ou de morbidités associées à cette dernière
CN113367349A (zh) * 2020-02-25 2021-09-10 内蒙古蒙牛乳业（集团）股份有限公司 用于肌肉衰减综合征的组合物、其制备方法和用途
CN114009510A (zh) * 2021-11-24 2022-02-08 北安宜品努卡乳业有限公司 一种低致敏性婴儿羊乳基配方乳粉及其制备方法
WO2022115347A1 (fr) * 2020-11-25 2022-06-02 Intrinsic Medicine, Inc. Procédés d'amélioration de la force musculaire et de la mobilité
CN114599232A (zh) * 2019-10-24 2022-06-07 菲仕兰坎皮纳荷兰公司 用于预防哮喘的包含2’-岩藻糖基乳糖的组合物
CN114641208A (zh) * 2019-11-27 2022-06-17 雀巢产品有限公司 用于降低应激障碍的新型组合物
US20220218737A1 (en) * 2019-05-24 2022-07-14 Cosucra Groupe Warcoing S.A. Composition comprising inulin and protein
WO2022155126A1 (fr) * 2021-01-12 2022-07-21 Intrinsic Medicine, Inc. Méthodes et compositions de prise en charge de la santé humaine au cours d'un voyage spatial
WO2022225786A1 (fr) * 2021-04-22 2022-10-27 Abbott Laboratories Procédés et compositions pour améliorer la force musculaire et/ou réduire la perte musculaire
EP4247178A1 (fr) * 2020-11-20 2023-09-27 DSM IP Assets B.V. Confiserie gélifiée comprenant un hmo
WO2023211146A1 (fr) * 2022-04-28 2023-11-02 (주)에이피테크놀로지 Composition contenant du 2'-fl pour améliorer, prévenir ou traiter des maladies provoquées par la réduction de dopamine
WO2024059052A1 (fr) * 2022-09-12 2024-03-21 Children's Hospital Los Angeles Composition comprenant au moins deux oligosaccharides
WO2024121153A1 (fr) * 2022-12-05 2024-06-13 Inbiose N.V. Utilisation d'un saccharide sialylé pour maintenir ou améliorer la mobilité chez un patient sain
EP4209220A4 (fr) * 2021-11-23 2024-08-28 Advanced Protein Technologies Corp. Composition destinée à améliorer, à prévenir ou à traiter l'atrophie musculaire ou la sarcopénie, contenant du 2'-fl
CN118872727A (zh) * 2023-12-29 2024-11-01 内蒙古蒙牛乳业（集团）股份有限公司 一种具有增强免疫力的人乳低聚糖组合物
WO2025229000A1 (fr) * 2024-04-30 2025-11-06 N.V. Nutricia Composition nutritionnelle et utilisations

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039749A2 (fr) * 1996-04-25 1997-10-30 Abbott Laboratories Procede de prevention et de traitement de la cachexie et de l'anorexie
WO2005039597A2 (fr) * 2003-10-24 2005-05-06 N.V. Nutricia Oligosaccharides immunomodulatrices
WO2007050656A2 (fr) * 2005-10-24 2007-05-03 Nestec S.A. Preparation de fibres alimentaires et leur methode d'administration
WO2007069900A1 (fr) * 2005-12-16 2007-06-21 N.V. Nutricia Utilisation de fibres alimentaires solubles contre la perte musculaire
WO2011060123A1 (fr) * 2009-11-12 2011-05-19 Nestec S.A. Composition nutritionnelle permettant de favoriser l'équilibre de microbiotes digestifs et la santé
WO2011094557A1 (fr) * 2010-01-29 2011-08-04 Abbott Laboratories Emulsions nutritionnelles comprenant du beta-hydroxy-beta-methylbutyrate de calcium
EP2614725A1 (fr) * 2012-01-13 2013-07-17 Abbott Laboratories Utilisation de systèmes de carbohydrates spécifiques pendant la grossesse pour améliorer le développement et la formation de masse corporelle maigre et réduire les effets nocifs sur la santé plus tard dans la progéniture
WO2014100191A1 (fr) * 2012-12-18 2014-06-26 Abbott Laboratories Compositions nutritives contenant des oligosaccharides alimentaires neuroprotecteurs
WO2014155056A1 (fr) * 2013-03-28 2014-10-02 Clasado Inc Composition de galacto-oligosaccharides utilisée pour prévenir ou traiter le dysfonctionnement cognitif et les perturbations émotionnelles dans les maladies neuropsychiatriques ou le vieillissement

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997039749A2 (fr) * 1996-04-25 1997-10-30 Abbott Laboratories Procede de prevention et de traitement de la cachexie et de l'anorexie
WO2005039597A2 (fr) * 2003-10-24 2005-05-06 N.V. Nutricia Oligosaccharides immunomodulatrices
WO2007050656A2 (fr) * 2005-10-24 2007-05-03 Nestec S.A. Preparation de fibres alimentaires et leur methode d'administration
WO2007069900A1 (fr) * 2005-12-16 2007-06-21 N.V. Nutricia Utilisation de fibres alimentaires solubles contre la perte musculaire
WO2011060123A1 (fr) * 2009-11-12 2011-05-19 Nestec S.A. Composition nutritionnelle permettant de favoriser l'équilibre de microbiotes digestifs et la santé
WO2011094557A1 (fr) * 2010-01-29 2011-08-04 Abbott Laboratories Emulsions nutritionnelles comprenant du beta-hydroxy-beta-methylbutyrate de calcium
EP2614725A1 (fr) * 2012-01-13 2013-07-17 Abbott Laboratories Utilisation de systèmes de carbohydrates spécifiques pendant la grossesse pour améliorer le développement et la formation de masse corporelle maigre et réduire les effets nocifs sur la santé plus tard dans la progéniture
WO2014100191A1 (fr) * 2012-12-18 2014-06-26 Abbott Laboratories Compositions nutritives contenant des oligosaccharides alimentaires neuroprotecteurs
WO2014155056A1 (fr) * 2013-03-28 2014-10-02 Clasado Inc Composition de galacto-oligosaccharides utilisée pour prévenir ou traiter le dysfonctionnement cognitif et les perturbations émotionnelles dans les maladies neuropsychiatriques ou le vieillissement

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS, [online] 1 April 2011 (2011-04-01), KIM EUN JIN: "Effects of Fructooligosaccharides Intake on Body Weight, Lipid Profiles, and Calcium Status among Korean College Students", XP002734535, retrieved from BIOSIS Database accession no. PREV201300066604 *

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107280012A (zh) * 2016-03-30 2017-10-24 邢亮 一种具有心血管调理作用的食疗产品及其制备方法
WO2018020473A1 (fr) * 2016-07-28 2018-02-01 Fonterra Co-Operative Group Limited Produit laitier et procédé associé
CN109715169A (zh) * 2016-07-28 2019-05-03 方塔拉合作集团有限公司 乳制品和工艺
US10729707B2 (en) 2016-07-28 2020-08-04 Fonterra Co-Operative Group Limited Dairy product and process
US12016869B2 (en) 2016-07-28 2024-06-25 Fonterra Co-Operative Group Limited Dairy product and process
AU2017302181B2 (en) * 2016-07-28 2023-02-02 Fonterra Co-Operative Group Limited Dairy product and process
US10485253B2 (en) 2017-08-21 2019-11-26 Mustapha Benmoussa Method of microalgal biomass processing for high-value chemicals production, the resulting composition of butyrogenic algal slowly fermenting dietary fiber, and a way to improve colon health using a slowly fermenting butyrogenic algal dietary fiber
US10834949B2 (en) 2017-08-21 2020-11-17 Mustapha Benmoussa Method of microalgal biomass processing for high-value chemicals production, the resulting composition of butyrogenic algal slowly fermenting dietary fiber, and a way to improve colon health using a slowly fermenting butyrogenic algal dietary fiber
WO2019071021A3 (fr) * 2017-10-04 2020-04-02 The Regents Of The University Of California Oligosaccharides immunomodulateurs
CN111356461A (zh) * 2017-10-04 2020-06-30 加利福尼亚大学董事会 免疫调节性低聚糖
AU2018346500B2 (en) * 2017-10-04 2024-10-24 The Regents Of The University Of California Immunomodulatory oligosaccharides
CN111248289A (zh) * 2018-11-30 2020-06-09 内蒙古伊利实业集团股份有限公司 一种组合物、其制备方法及用途
US20220218737A1 (en) * 2019-05-24 2022-07-14 Cosucra Groupe Warcoing S.A. Composition comprising inulin and protein
WO2021048440A1 (fr) * 2019-09-13 2021-03-18 Basf Se Composition pour le traitement de maladies neurodégénératives
CN114599232A (zh) * 2019-10-24 2022-06-07 菲仕兰坎皮纳荷兰公司 用于预防哮喘的包含2’-岩藻糖基乳糖的组合物
CN114641208A (zh) * 2019-11-27 2022-06-17 雀巢产品有限公司 用于降低应激障碍的新型组合物
WO2021123253A1 (fr) * 2019-12-19 2021-06-24 Basf Se Composition pour le traitement de la (pré)hyperglycémie et/ou de morbidités associées à cette dernière
CN113367349B (zh) * 2020-02-25 2024-03-12 内蒙古蒙牛乳业（集团）股份有限公司 用于肌肉衰减综合征的组合物、其制备方法和用途
CN113367349A (zh) * 2020-02-25 2021-09-10 内蒙古蒙牛乳业（集团）股份有限公司 用于肌肉衰减综合征的组合物、其制备方法和用途
EP4247178A1 (fr) * 2020-11-20 2023-09-27 DSM IP Assets B.V. Confiserie gélifiée comprenant un hmo
US20240000099A1 (en) * 2020-11-20 2024-01-04 Dsm Ip Assets B.V. Gelled confection comprising hmo
WO2022115347A1 (fr) * 2020-11-25 2022-06-02 Intrinsic Medicine, Inc. Procédés d'amélioration de la force musculaire et de la mobilité
WO2022155126A1 (fr) * 2021-01-12 2022-07-21 Intrinsic Medicine, Inc. Méthodes et compositions de prise en charge de la santé humaine au cours d'un voyage spatial
WO2022225786A1 (fr) * 2021-04-22 2022-10-27 Abbott Laboratories Procédés et compositions pour améliorer la force musculaire et/ou réduire la perte musculaire
EP4209220A4 (fr) * 2021-11-23 2024-08-28 Advanced Protein Technologies Corp. Composition destinée à améliorer, à prévenir ou à traiter l'atrophie musculaire ou la sarcopénie, contenant du 2'-fl
US12168020B2 (en) 2021-11-23 2024-12-17 Advanced Protein Technologies Corp. Method for ameliorating, preventing or treating muscular atrophy or sarcopenia by administering composition comprising 2′-fucosyllactose as active ingredient
CN114009510A (zh) * 2021-11-24 2022-02-08 北安宜品努卡乳业有限公司 一种低致敏性婴儿羊乳基配方乳粉及其制备方法
WO2023211146A1 (fr) * 2022-04-28 2023-11-02 (주)에이피테크놀로지 Composition contenant du 2'-fl pour améliorer, prévenir ou traiter des maladies provoquées par la réduction de dopamine
WO2024059052A1 (fr) * 2022-09-12 2024-03-21 Children's Hospital Los Angeles Composition comprenant au moins deux oligosaccharides
WO2024121153A1 (fr) * 2022-12-05 2024-06-13 Inbiose N.V. Utilisation d'un saccharide sialylé pour maintenir ou améliorer la mobilité chez un patient sain
CN118872727A (zh) * 2023-12-29 2024-11-01 内蒙古蒙牛乳业（集团）股份有限公司 一种具有增强免疫力的人乳低聚糖组合物
CN118872727B (zh) * 2023-12-29 2025-01-21 内蒙古蒙牛乳业（集团）股份有限公司 一种具有增强免疫力的人乳低聚糖组合物
WO2025229000A1 (fr) * 2024-04-30 2025-11-06 N.V. Nutricia Composition nutritionnelle et utilisations

Similar Documents

Publication Publication Date Title
WO2016029113A1 (fr) Procédés d'augmentation de la production endogène de bêta-hydroxy-bêta-méthylbutyrate
JP7301093B2 (ja) 過敏性腸症候群の治療のための合成組成物および方法
US11529364B2 (en) Synthetic composition for treating metabolic disorders
RU2420210C2 (ru) Высококалорийная питательная добавка
EP2708145B1 (fr) Compositions nutritionnelles pour utilisation dans des méthodes pour moduler les niveaux de corticostérone chez des individus psychologiquement stressés
BR112020010843A2 (pt) oligossacarídeos do leite humano e composições sintéticas desses para modulação da microbiota
WO2015105981A2 (fr) Essentialité conditionnelle de hmb
US10987368B2 (en) Synthetic composition for preventing or treating CVD
KR20220106790A (ko) Hmo의 혼합물
CN111526879A (zh) 用于减少或预防疲劳和/或改善注意力或专注力的一种或多种hmo
WO2017215721A1 (fr) Compositions synthétiques comprenant des oligosaccharides du lait humain pour l'utilisation dans la prévention et le traitement de troubles
US10881674B2 (en) Synthetic composition for treating metabolic disorders
CN104135872A (zh) 妊娠期间特定碳水化合物系统用于影响后代的用途
US10835544B2 (en) Synthetic composition for regulating satiety
US20160029679A1 (en) Use of specific carbohydrate systems during pregnancy for preventing fat accumulation in pregnant women
US20150305387A1 (en) Nutritional composition with non digestible oligosaccharides
EP2614725A1 (fr) Utilisation de systèmes de carbohydrates spécifiques pendant la grossesse pour améliorer le développement et la formation de masse corporelle maigre et réduire les effets nocifs sur la santé plus tard dans la progéniture
CN119584866A (zh) 用于抑制肥大细胞脱颗粒的叶黄素
EP2614724A1 (fr) Utilisation de systèmes de carbohydrates spécifiques pendant la grossesse pour réduire les effets nocifs sur la santé plus tard dans la progéniture
WO2024223906A1 (fr) Composition destinée à être utilisée chez un sujet
WO2025196272A1 (fr) Combinaison de mélanges de hmo avec mfgm et leur utilisation
HK1195856B (en) Nutritional compositions for use in methods for modulating corticosterone levels in psychologically stressed individuals
HK1187498A (en) Use of specific carbohydrate systems during pregnancy for reducing adverse health effects later in life in offspring

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15757395

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15757395

Country of ref document: EP

Kind code of ref document: A1